Employer Health Costs Hit Record Highs as Surprise Billing Laws and Drug Prices Drive 2027 Spikes

Employer health insurance costs are rising at the fastest pace in two decades, with double-digit increases already hitting 2026 and projected to spike further in 2027. A new survey indicates 36% of firms face 10% or more premium hikes, driven by cancer care, specialty drugs, and the unintended financial consequences of the No Surprises Act. Employers are shifting costs to workers through higher deductibles and copays, while cutting coverage for expensive weight-loss drugs like GLP-1s. These trends are squeezing wage growth and forcing companies to rethink pharmacy benefit managers and plan structures.
Key points
- A Gallagher survey of 3,700 firms found 36% reported premium increases of 10% or more in their latest renewal cycle.
- Cancer care is the top cost driver for 70% of firms, with advanced treatments costing up to $10,000 monthly.
- The No Surprises Act’s independent dispute resolution process is now a top-three driver of cost increases for employers, according to Aetna.
- Marsh projects an 8.2% average cost increase for 2027, the highest since 2003, after accounting for employer cost-cutting measures.
- Employers are increasingly self-insuring and moving away from major pharmacy benefit managers like CVS Caremark and Optum Rx to control drug costs.
- GLP-1 weight-loss drug coverage is being restricted or dropped by many firms as costs exceed the $350 monthly threshold for cost-effectiveness.
Background
This surge follows a period of rising premiums and deductibles, with 2026 family premiums reaching $28,303. Earlier in 2026, employers began slashing GLP-1 coverage due to soaring costs, with coverage among large firms dropping from 57% to 53%. The current crisis extends beyond weight-loss drugs to include broader specialty medications and cancer treatments, reflecting a systemic shift in how employers manage health budgets.
How outlets are covering it
Axios highlights the Gallagher survey data, emphasizing that double-digit increases are already occurring in 2026, not just projected for 2027. It points to the No Surprises Act’s arbitration process as a major cost driver. Newsday focuses on the regional impact in Long Island and the national 8.2% projected increase for 2027, noting that employers are passing costs to workers through higher deductibles. Bloomberg notes that health costs rose 6.4% in the year through September 2026, matching the fastest increase since 2005, and links this to slow wage growth. The Atlantic argues that the No Surprises Act has become a perverse tool for extracting money from insurers, contributing to the 11% projected rise in 2027. All sources agree on the severity of the cost crunch but differ on the primary drivers, with Axios and The Atlantic emphasizing the No Surprises Act, while Marsh and Newsday focus on drug costs and chronic disease.
Why it matters
The rising cost of employer-provided health insurance is directly impacting the labor market by constraining wage growth and forcing employers to shift costs to employees. This affects approximately 160 million Americans covered through work, leading to higher out-of-pocket expenses, reduced benefits, and potential gaps in coverage. The situation is unsustainable for many employers, who are forced to choose between cutting pay raises, reducing benefits, or passing on costs to workers. The long-term implications include increased financial stress for households and potential reductions in healthcare access for those who cannot afford higher deductibles and copays.
What to watch
Employers are expected to continue shifting costs to workers through higher deductibles, copays, and reduced coverage. There is a growing trend toward self-insuring and moving away from traditional pharmacy benefit managers to gain more control over drug costs. Congress is expected to consider changes to PBM business practices to lower drug prices and improve transparency. Additionally, there is a rise in worker lawsuits against plan sponsors for failing to negotiate reasonable drug prices. The impact of GLP-1 drug costs will continue to be a major factor, with employers exploring alternative coverage models such as direct-to-consumer sales and defined subsidies.
- Employer health cost crunch is worse than projected Axios
- LI health insurance costs to rise significantly in 2027 Newsday
- American workers face a surge in health costs The Economist
- Rising Healthcare Costs Have Employers Choosing Between Premiums and Pay Raises Bloomberg.com
- The Perverse Reason Health-Care Costs Are About to Surge The Atlantic
Want the full story? Read the original reporting
Read on Axios